Treatment of Wilson's Disease with Zinc II. Validation of Oral 64Copper with Copper Balance
Treatment of Wilson's Disease with Zinc II. Validation of Oral 64Copper with Copper Balance
复制标题
用锌 II 治疗威尔逊氏病。
DOI：
--
复制
发表时间：
1986
影响因子：
3.1
通讯作者：
R. Dick
中科院分区：
文献类型：
--
作者：
G. Hill;G. Brewer;J. Juni;A. Prasad;R. Dick
锌作为一种治疗剂，以控制铜平衡威尔逊病患者的疗效已被记录与平衡研究。在试图开发一种更简单，更快的工具来评估锌治疗的充分性，一种技术，测量摄入到血液中的一个小的口服剂量的64铜结合铜平衡进行了研究。9例肝豆状核变性患者服用D-青霉胺、三烯或不服用药物后，其血中~（64）Cu的平均峰值摄取率为6.04 ± 2.74%，与正常对照组相当。7例接受锌治疗的患者治疗后平均摄取量显著降低，为0.79 ± 1.05%。这些数据表明，锌治疗对肝豆状核变性患者血铜摄取的预防作用可以通过64铜摄取来评估，在中性或负铜平衡的患者中，峰值摄取低于1%。
The efficacy of zinc as a therapeutic agent to control copper balance in Wilson's disease patients has been previously documented with balance studies. In an attempt to develop a simpler and faster tool for evaluating the adequacy of zinc therapy, a technique that measures the uptake into blood of a small oral dose of 64copper was studied in conjuction with copper balance. The mean peak 64copper uptake into blood of nine Wilson's disease patients on D-penicillamine, trien, or no medication was 6.04 ± 2.74%, comparable with normal controls. Seven patients on zinc therapy had a markedly and significantly reduced mean uptake of 0.79 ± 1.05% after treatment. The data demonstrate that the prevention of copper uptake into blood in Wilson's disease patients by zinc therapy can be evaluated by 64copper uptake and that peak uptakes of less than 1% occur in patients with neutral or negative copper balance.